Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 2, 2014, Pages 308-318

  Climent, Miguel Ángel ^a   León Mateos, Luis ^b   González del Alba, Aránzazu ^c   Pérez Valderrama, Begoña ^d   Méndez Vidal, MaJosé ^e   Mellado, Begoña ^f   Arranz, José Ángel ^g   Sánchez Hernández, Alfredo ^h   Cassinello, Javier ⁱ   Olmos, David ^j   Carles, Joan ^k  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b Instituto de Investigación Sanitaria Galicia Sur   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h Plastic and Reconstructive Surgery Service   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^j Structural Biology and Biocomputing Programme   (Spain)

^k VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

more..

Author keywords

Asymptomatic; Castration resistant prostate carcinoma; Chemotherapy; Hormonal therapies; Recommendations; Symptomatic

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CABAZITAXEL; CALCIUM; CORTICOSTEROID; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GONADORELIN DERIVATIVE; MITOXANTRONE; OPIATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; BACKACHE; BLOOD TOXICITY; BONE METASTASIS; BRIEF PAIN INVENTORY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION SENSITIVE PROSTATE CANCER; CHILL; CIRCULATING TUMOR CELL; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAW OSTEONECROSIS; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MEDICAL SOCIETY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEIZURE; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; VISCERAL METASTASIS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84955202085     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.019     Document Type: Review

References (57)

1. European cancer observatory. [cited April 2014]; Available from: http://eco.iarc.fr/EUCAN/.
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(Oct (15)):1502-1512.
3. Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986, 89(2 Suppl):2S-3S.
4. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26(Mar (7)):1148-1159.
5. Taylor C.D., Elson P., Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993, 11(11):2167-2172.
6. Hussain M., Wolf M., Marshall E., Crawford E.D., Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994, 12(9):1868-1875.
7. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17(11):3461-3467.
8. Sartor A.O., Tangen C.M., Hussain M.H., et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008, 112(Jun (11)):2393-2400.
9. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(Jul (5)):411-422.
10. Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368(Jan (2)):138-148.
11. Beer T.M., Armstrong A.J., Sternberg C.N., et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. J Clin Oncol 2014, 32(Suppl 4):LBA1.
12. Beer T.M., Armstrong A.J., Rathkopf D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371(Jun):1755-1756.
13. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13(Nov (21)):6396-6403.
14. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., Tannock A.I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14(May (9)):2763-2767.
15. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351(Oct (15)):1513-1520.
16. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26(Jan (2)):242-245.
17. Buonerba C., Palmieri G., Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol 2010, 58(Oct (4)):636-637.
18. Di Lorenzo G., Buonerba C., Faiella A., et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011, 107(Jan (2)):234-239.
19. Sweeney C., Chen Y.-H., Carducci M.A., et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. ASCO Meeting Abstr 2014, 32(June (Suppl 18)):LBA2.
20. Gravis G., Fizazi K., Joly F., et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013, 14(2):149-158.
21. Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fossa S.D. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369(3):213-223.
22. Parker C., Nilsson S., Vogelzang N.J., Lloyd A.J., Stadacher K. Update survival, quality of life (QOL), and safety data of radium-223 chloride (223Ra) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Ann Oncol 2012, 2(October (Suppl 2012)). poster 898.
23. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004, 90(Jun (12)):2317-2325.
24. Jung M.E., Ouk S., Yoo D., et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010, 53(Apr (7)):2779-2796.
25. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364(May (21)):1995-2005.
26. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367(Sep (13)):1187-1197.
27. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376(Oct (9747)):1147-1154.
28. Bahl A., Oudard S., Tombal B., et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013, 24(9):2402-2408.
29. Azria D., Massard C., Tosi D., et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. ASCO Meeting Abstr 2012, 30(February (Suppl 5)):149.
30. Gallardo E., Arranz J.A., Maroto J.P., Leon L.A., Bellmunt J. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Crit Rev Oncol Hematol 2013, 88(Nov (2)):357-367.
31. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(Oct (19)):1458-1468.
32. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96(Jun (11)):879-882.
33. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(Mar (9768)):813-822.
34. Antonarakis E.S., Lu C., Wang H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014, 371(Sep (11)):1028-1038.
35. Fitzpatrick J.M., de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2013, 65(Jul):1198-1204.
36. van Soest R.J., van Royen M.E., de Morree E.S., et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013, 49(Dec (18)):3821-3830.
37. Aggarwal R., Halabi S., Kelly W.K., et al. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer 2013, 119(Oct (20)):3636-3643.
38. Mezynski J., Pezaro C., Bianchini D., et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann Oncol 2012, 23(11):2943-2947.
39. Aggarwal R., Harris A., Formaker C., et al. Response to subsequent Docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 2014, 12(Mar):e167-e172.
40. Pezaro C., Omlin A.G., Altavilla A., et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014, 66:459-465.
41. Al Nakouzi N., Le Moulec S., Albiges L., et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014, (May).
42. Badrising S., van der Noort V., van Oort I.M., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014, 120(Apr (7)):968-975.
43. Schrader A.J., Boegemann M., Ohlmann C.H., et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014, 65(1):30-36.
44. Loriot Y., Bianchini D., Ileana E., et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013, 24(7):1807-1812.
45. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14(Oct (19)):6302-6309.
46. Olmos D., Arkenau H.T., Ang J.E., et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009, 20(1):27-33.
47. Danila D.C., Heller G., Gignac G.A., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13(Dec (23)):7053-7058.
48. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10(3):233-239.
49. Yap T.A., Lorente D., Omlin A., Olmos D., de Bono J.S. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014, 20(May (10)):2553-2568.
50. Olmos D., Brewer D., Clark J., et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012, 13(11):1114-1124.
51. Ross R.W., Galsky M.D., Scher H.I., et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 2012, 13(11):1105-1113.
52. Alix-Panabieres C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215.
53. Ries L.A.G., Melbert D., Krapcho M. Cancer statistics review, 1975-2005 2008, National Cancer Institute, Bethesda, MD, [cited December 2009]. Available from 〈http://seer.cancer.gov/archive/csr/1975_2005/〉.
54. Droz J.P., Aapro M., Balducci L., et al. Management of prostate cancer in older patients: updated recommendations of a working Group of the International Society of Geriatric Oncology. Lancet Oncol 2014, 15(Aug (9)):e404-e414.
55. Droz J.P., Balducci L., Bolla M., et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010, 106(Aug (4)):462-469.
56. Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13(10):983-992.
57. Droz J.P., Balducci L., Bolla M., et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010, 73(1):68-91.